InSyBio Precision Chronic Pain Treatment Tool

For Patients!

98.1% of the patients that were classified into the responders group presented a decrease in the pain scales and in the total number of administered drugs 3-6 months after having our test.
InSyBio Precision Chronic Pain Treatment Tool has been developed for the US population, and is mainly intended for use in the US. All medical decisions need to be taken by a patient in consultation with their doctor. The authors and the sponsors of this tool accept no responsibility for clinical use or misuse of the machine learning empowered prognostic scores or any other detail displayed in our tool.